Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2016 | 1 |
2019 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Articles
found by citation matching
Page 1
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
BMC Cancer. 2019 May 28;19(1):504. doi: 10.1186/s12885-019-5600-x.
BMC Cancer. 2019.
PMID: 31138244
Free PMC article.
Clinical Trial.
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
Baertsch MA, Schlenzka J, Mai EK, Merz M, Hillengaß J, Raab MS, Hose D, Wuchter P, Ho AD, Jauch A, Hielscher T, Kunz C, Luntz S, Klein S, Schmidt-Wolf IG, Goerner M, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Salwender H, Scheid C, Nogai A, Haenel M, Lindemann HW, Martin H, Noppeney R, Weisel K, Goldschmidt H.
Baertsch MA, et al.
BMC Cancer. 2016 Apr 25;16:290. doi: 10.1186/s12885-016-2321-2.
BMC Cancer. 2016.
PMID: 27114074
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite